6 |
Title |
CB[6]/DAH-HA Hydrogels Encapsulating MSCs |
7 |
Composition |
Hyaluronic Acid, Flt1 Cucurbituril[6], Mesenchymal stem cells(MSCs), Adenovirus, Chemical drugs |
8 |
Application |
- Cancer therapy
- Stroke, limb ischemia
|
9 |
Competitive Advantage |
- Non-toxic, stable, in situ forming hydrogel to encapsulate engineered MSCs (eMCSs)
- Long-term transgene expression of engineered MSCs
|
10 |
Stage of Development |
Preclinical |
11 |
Data Files |
- In Vitro transgene expression ability
- In Vivo cell viability in mice
- In Vivo hydrogel degradation data in mice
- In Vivo cancer therapy in mice (single, repeated injection)
|
12 |
Test Model Drug |
Dexamethasone, Retinoic acid, IL-12 expressing MSCs |
13 |
Representative Figure |
|